Epigenomics AG / Key word(s): Capital Increase/Miscellaneous
16.10.2014 09:30
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin (Germany) and Germantown (USA), October 16, 2014 - Epigenomics AG
(ISIN: DE000A11QW50, OTCQX: EPGNY) announces today that the Company is
raising USD 5.3 million (EUR 4.2 million) in a share capital increase.
BioChain Institute, Inc. will subscribe a total of 1,351,089 Epigenomics
shares which will be issued under exclusion of the statutory subscription
right of the shareholders.
The Executive Board of Epigenomics AG, with approval of the Supervisory
Board, today resolved on the increase of the of the Company's share capital
by the amount of EUR 1,351,089 by issuance of 1,351,089 new shares from
the Authorized Capital 2014/I against contribution in cash. The issue price
has been set at EUR 3.08 per share, based on the XETRA closing price of the
day prior to the announcement, Wednesday, October 15, 2014. After
registration of the capital increase on or around November 21, 2014, the
subscribed capital of Epigenomics AG will increase from currently EUR
13,517,558 to EUR 14,868,647.
Epigenomics AG intends to use the net proceeds from the capital increase to
finance its current operations and to strengthen the distribution
capabilities for its lead product Epi proColon(R), a convenient blood-based
test for the early detection of colorectal cancer.
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology, which
may be sold at some future time in the U.S. have not been established.
16.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
16. October 2014 - 0:00 (CEST)